Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 1077-1087

  Tschan, M P ^a   Vonlanthen, S ^a   Cajot, J F ^a   Peters, U R ^a   Oppliger, E ^a   Betticher, D C ^a   Yarbrough, W G ^a   Fey, M F ^a   Tobler, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute myeloblastic leukemia; AML; Cell cycle; CKI; p14ARF; p16INK4a

Indexed keywords

CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PROTEIN P14; PROTEIN P16; UNCLASSIFIED DRUG; PROTEIN P14ARF; PROTEIN P16INK4A; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; TUMOR SUPPRESSOR GENE; ACUTE DISEASE; COMPARATIVE STUDY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY;

ACUTE DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0034741637     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097728     Document Type: Article

References (48)

1. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies
2. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
3. The INK4a/ARF tumor suppressor: One gene-two products-two pathways
4. Role of the p16 tumor suppressor gene in cancer
5. Cell-cycle regulators and cancer
6. The retinoblastoma protein and cell cycle control
7. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
8. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
9. Identification of a cryptic nucleolar-localization signal in MDM2
10. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex
11. p16 gene homozygous deletions in acute lymphoblastic leukemia
12. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
13. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias
14. Recent progress in molecular mechanisms of leukemogenesis: The cyclin- dependent kinase 4-inhibitor gene in human leukemias
15. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
16. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
17. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level
18. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
19. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
20. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
21. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia
22. Expression of p16INK4A and p14ARF in hematological malignancies
23. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage
24. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes
25. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
26. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
27. Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY)
28. Comparative detection and quantitation of human CDK inhibitor mRNA expression of p15INK4B, p16INK4A, p16beta, p18INK4C, p19INK4D, p21WAF1, p27KIP1 and p57KIP2 by RT-PCR using a polycompetitive internal standard
29. ARF/p16β in Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia
30. The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells
31. Use of a new fluorogenic phosphatase substrate in immunohistochemical applications
32. Complex structure and regulation of the P16 (MTS1) locus
33. p16INK4A and p15INK4B gene deletions in primary leukemias
34. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias
35. Splicing into senescence: The curious case of p16 and p19ARF
36. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
37. Cell differentiation in acute myeloid leukemia
38. High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach
39. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue
40. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product
41. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines
42. Increased p16 levels correlate with pRb alterations in human urothelial cells
43. The retinoblastoma gene product in acute myeloid leukemia: A possible involvement in promyelocytic leukemia
44. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16INK4a/MTS1 gene
45. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer
46. A simple p53 functional assay for screening cell lines, blood, and tumors
47. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia
48. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia